Handel Denali Therapeutics - DNLI CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.09 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
Gebyr natten over, tid | 22:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 32.6 |
Åben* | 32.49 |
1-Års Ændring* | -4.19% |
Dagens Spænd* | 31.5 - 32.67 |
52-Ugers Spænd | 20.24-39.43 |
Gennemsnitlig Volumen (10 dage) | 623.19K |
Gennemsnitlig Volumen (3 måneder) | 13.58M |
Market Cap | 4.44B |
P/E-forhold | -100.00K |
Udestående aktier | 135.81M |
Omsætning | 110.69M |
EPS | -2.46 |
Dividend (Udbytte %) | N/A |
Beta | 1.37 |
Næste indtjeningsopgørelse | Feb 27, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 31.67 | -0.17 | -0.53% | 31.84 | 32.76 | 31.47 |
Feb 2, 2023 | 32.60 | 1.57 | 5.06% | 31.03 | 32.60 | 30.45 |
Feb 1, 2023 | 30.84 | 0.86 | 2.87% | 29.98 | 31.37 | 29.97 |
Jan 31, 2023 | 30.20 | 0.22 | 0.73% | 29.98 | 30.79 | 29.97 |
Jan 30, 2023 | 30.07 | -1.42 | -4.51% | 31.49 | 31.71 | 29.93 |
Jan 27, 2023 | 31.44 | 0.97 | 3.18% | 30.47 | 31.94 | 30.47 |
Jan 26, 2023 | 30.50 | 0.24 | 0.79% | 30.26 | 31.02 | 30.01 |
Jan 25, 2023 | 30.76 | 0.65 | 2.16% | 30.11 | 30.78 | 29.67 |
Jan 24, 2023 | 30.23 | 1.21 | 4.17% | 29.02 | 30.58 | 28.97 |
Jan 23, 2023 | 29.65 | 0.63 | 2.17% | 29.02 | 29.72 | 28.45 |
Jan 20, 2023 | 29.00 | -0.56 | -1.89% | 29.56 | 29.56 | 28.58 |
Jan 19, 2023 | 29.18 | -0.33 | -1.12% | 29.51 | 29.71 | 28.80 |
Jan 18, 2023 | 30.03 | -0.21 | -0.69% | 30.24 | 30.85 | 29.67 |
Jan 17, 2023 | 30.06 | 1.09 | 3.76% | 28.97 | 30.20 | 28.75 |
Jan 13, 2023 | 29.05 | 0.35 | 1.22% | 28.70 | 29.56 | 28.62 |
Jan 12, 2023 | 29.16 | 1.53 | 5.54% | 27.63 | 29.19 | 26.95 |
Jan 11, 2023 | 27.62 | -0.20 | -0.72% | 27.82 | 27.98 | 26.73 |
Jan 10, 2023 | 28.06 | 0.54 | 1.96% | 27.52 | 28.51 | 27.34 |
Jan 9, 2023 | 27.77 | -0.59 | -2.08% | 28.36 | 28.69 | 27.72 |
Jan 6, 2023 | 28.83 | 0.25 | 0.87% | 28.58 | 29.36 | 27.86 |
Denali Therapeutics Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total omsætning | 0 | 0 | 129.16 | 26.678 | 335.659 | 48.661 |
Totale Driftsudgifter | 87.433 | 90.14 | 175.532 | 239.862 | 272.941 | 344.412 |
Salgs/Generelle/Admin. Udgifter, Total | 11.731 | 15.68 | 32.349 | 46.48 | 60.326 | 79.059 |
Forskning & Udvikling | 75.702 | 74.46 | 143.183 | 193.382 | 212.615 | 265.353 |
Driftsindtægter | -87.433 | -90.14 | -46.372 | -213.184 | 62.718 | -295.751 |
Renteindkomst (Udgift), Netto Ikke-Drift | 0.781 | 1.955 | 10.132 | 15.219 | 9.241 | 4.595 |
Netto Indkomst Før Skat | -86.652 | -88.185 | -36.24 | -197.965 | 71.959 | -291.156 |
Netto Indkomst Efter Skat | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Netto Indkomst Før Ekstra Ting | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Netto Indkomst | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Fortyndelsesændring | 0 | |||||
Fortyndet Netto Indkomst | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Fortyndet Vægtet Gennemsnit Aktier | 82.4239 | 87.4804 | 92.622 | 95.6082 | 112.703 | 121.525 |
Fortyndet EPS Uden Ekstraordinære Ting | -1.0513 | -1.00805 | -0.39127 | -2.06691 | 0.63118 | -2.39113 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
Fortyndet Normaliseret EPS | -1.0513 | -1.00805 | -0.39127 | -2.06691 | 0.63118 | -2.39113 |
Omsætning | 129.16 | 26.678 | 335.659 | 48.661 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total omsætning | 7.923 | 22.939 | 5.285 | 12.514 | 42.141 |
Omsætning | 7.923 | 22.939 | 5.285 | 12.514 | 42.141 |
Totale Driftsudgifter | 79.143 | 84.756 | 90.878 | 89.635 | 108.639 |
Salgs/Generelle/Admin. Udgifter, Total | 18.936 | 19.045 | 19.319 | 21.759 | 22.541 |
Forskning & Udvikling | 60.207 | 65.711 | 71.559 | 67.876 | 86.098 |
Driftsindtægter | -71.22 | -61.817 | -85.593 | -77.121 | -66.498 |
Renteindkomst (Udgift), Netto Ikke-Drift | 1.179 | 1.126 | 1.005 | 1.285 | 1.278 |
Netto Indkomst Før Skat | -70.041 | -60.691 | -84.588 | -75.836 | -65.22 |
Netto Indkomst Efter Skat | -70.041 | -60.691 | -84.588 | -75.261 | -65.22 |
Netto Indkomst Før Ekstra Ting | -70.041 | -60.691 | -84.588 | -75.261 | -65.22 |
Netto Indkomst | -70.041 | -60.691 | -84.588 | -75.261 | -65.22 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -70.041 | -60.691 | -84.588 | -75.261 | -65.22 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -70.041 | -60.691 | -84.588 | -75.261 | -65.22 |
Fortyndet Netto Indkomst | -70.041 | -60.691 | -84.588 | -75.261 | -65.22 |
Fortyndet Vægtet Gennemsnit Aktier | 120.885 | 121.291 | 121.742 | 122.172 | 122.674 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.5794 | -0.50037 | -0.69481 | -0.61603 | -0.53165 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.5794 | -0.50037 | -0.69481 | -0.61603 | -0.53165 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale Nuværende Aktiver | 181.955 | 409.607 | 480.836 | 430.031 | 1495.66 | 897.234 |
Likvider og Kortsigtede Investeringer | 178.331 | 406.226 | 464.297 | 415.356 | 1469.7 | 865.407 |
Likvider & Lignende | 39.853 | 218.375 | 77.123 | 79.449 | 507.144 | 293.477 |
Kortsigtede Investeringer | 138.478 | 187.851 | 387.174 | 335.907 | 962.553 | 571.93 |
Totale Tilgodehavender, Netto | 0.438 | 0.464 | 1.182 | 5.674 | 1.226 | |
Accounts Receivable - Trade, Net | 0.438 | 0.464 | 1.182 | |||
Prepaid Expenses | 3.186 | 2.917 | 15.357 | 14.675 | 20.284 | 30.601 |
Total Assets | 271.067 | 486.721 | 661.984 | 553.231 | 1604.28 | 1404.16 |
Property/Plant/Equipment, Total - Net | 15.262 | 14.923 | 25.162 | 80.655 | 73.464 | 69.608 |
Property/Plant/Equipment, Total - Gross | 16.85 | 19.592 | 37.172 | 92.928 | 94.266 | 98.952 |
Accumulated Depreciation, Total | -1.588 | -4.669 | -12.01 | -12.273 | -20.802 | -29.344 |
Long Term Investments | 73.08 | 61.25 | 147.881 | 39.886 | 32.699 | 425.449 |
Other Long Term Assets, Total | 0.77 | 0.941 | 8.105 | 2.659 | 2.462 | 11.871 |
Total Current Liabilities | 9.106 | 14.164 | 32.786 | 45.344 | 71.699 | 378.245 |
Accounts Payable | 1.963 | 2.716 | 1.891 | 2.59 | 1.071 | 4.779 |
Accrued Expenses | 6.442 | 10.53 | 18.472 | 24.007 | 47.145 | 53.165 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.701 | 0.918 | 12.423 | 18.747 | 23.483 | 320.301 |
Total Liabilities | 16.548 | 20.925 | 115.139 | 158.341 | 453.749 | 441.871 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 7.442 | 6.761 | 82.353 | 112.997 | 382.05 | 63.626 |
Total Equity | 254.519 | 465.796 | 546.845 | 394.89 | 1150.53 | 962.291 |
Redeemable Preferred Stock | 348.673 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.344 | 1.201 | 1.273 | 1.288 | 1.531 | 1.548 |
Additional Paid-In Capital | 9.387 | 656.66 | 774.158 | 818.803 | 1503.66 | 1608.24 |
Retained Earnings (Accumulated Deficit) | -103.512 | -191.697 | -227.937 | -425.551 | -354.415 | -644.996 |
Other Equity, Total | -0.373 | -0.368 | -0.649 | 0.35 | -0.245 | -2.499 |
Total Liabilities & Shareholders’ Equity | 271.067 | 486.721 | 661.984 | 553.231 | 1604.28 | 1404.16 |
Total Common Shares Outstanding | 82.4239 | 87.4804 | 94.6624 | 96.1899 | 120.531 | 122.283 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 1431.62 | 1341.74 | 1055.51 | 897.234 | 988.436 |
Likvider og Kortsigtede Investeringer | 1413.15 | 1308.93 | 1039.18 | 865.407 | 957.522 |
Likvider & Lignende | 435.321 | 485.68 | 394.553 | 293.477 | 104.953 |
Kortsigtede Investeringer | 977.827 | 823.251 | 644.622 | 571.93 | 852.569 |
Totale Tilgodehavender, Netto | 2.511 | 16.785 | 1.194 | 1.226 | 0 |
Prepaid Expenses | 15.963 | 16.029 | 15.14 | 30.601 | 30.914 |
Total Assets | 1547.86 | 1509.81 | 1449.97 | 1404.16 | 1320.86 |
Property/Plant/Equipment, Total - Net | 73.612 | 71.972 | 71.208 | 69.608 | 67.942 |
Long Term Investments | 38.885 | 92.522 | 319.472 | 425.449 | 250.268 |
Other Long Term Assets, Total | 3.739 | 3.576 | 3.777 | 11.871 | 14.212 |
Total Current Liabilities | 54.61 | 51.412 | 54.251 | 378.245 | 341.24 |
Accounts Payable | 1.626 | 4.235 | 4.817 | 4.779 | 3.358 |
Accrued Expenses | 36.529 | 37.984 | 44.672 | 53.165 | 44.542 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 16.455 | 9.193 | 4.762 | 320.301 | 293.34 |
Total Liabilities | 442.505 | 437.11 | 437.689 | 441.871 | 402.931 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 387.895 | 385.698 | 383.438 | 63.626 | 61.691 |
Total Equity | 1105.35 | 1072.7 | 1012.28 | 962.291 | 917.927 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
Common Stock | 1.537 | 1.541 | 1.545 | 1.548 | 1.554 |
Additional Paid-In Capital | 1528.5 | 1556.68 | 1580.99 | 1608.24 | 1635.84 |
Retained Earnings (Accumulated Deficit) | -424.456 | -485.147 | -569.735 | -644.996 | -710.216 |
Other Equity, Total | -0.232 | -0.368 | -0.521 | -2.499 | -9.251 |
Total Liabilities & Shareholders’ Equity | 1547.86 | 1509.81 | 1449.97 | 1404.16 | 1320.86 |
Total Common Shares Outstanding | 121.147 | 121.532 | 122.011 | 122.283 | 122.858 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto indkomst/Startlinje | -86.652 | -88.185 | -36.24 | -197.614 | 71.136 | -290.581 |
Likvider Fra Driftsaktiviteter | -71.908 | -76.635 | 50.116 | -151.576 | 416.152 | -211.389 |
Likvider Fra Driftsaktiviteter | 1.469 | 3.082 | 7.415 | 7.991 | 8.531 | 8.593 |
Ikke-Likvide Ting | 8.538 | 5.163 | 16.05 | 33.872 | 50.444 | 93.995 |
Ændringer i Driftskapital | 4.737 | 3.305 | 62.891 | 4.175 | 286.041 | -23.396 |
Likvider fra Investeringsaktiviteter | -219.004 | -41.166 | -287.422 | 147.712 | -623.206 | -21.626 |
Kapitaludgifter | -6.134 | -2.875 | -3.393 | -17.919 | -3.095 | -8.5 |
Andre Investerings-Cash-Flow-Ting, Total | -212.87 | -38.291 | -284.029 | 165.631 | -620.111 | -13.126 |
Likvider fra Financieringsaktiviteter | 300.476 | 296.323 | 97.019 | 6.19 | 634.749 | 19.348 |
Financiering af Cash-Flow-Ting | 0 | -1.386 | 0 | |||
Udstedelse (Pensionering) af Aktier, Netto | 300.476 | 296.323 | 98.405 | 6.19 | 634.749 | 19.348 |
Netto Ændring i Likviditet | 9.564 | 178.522 | -140.287 | 2.326 | 427.695 | -213.667 |
Udstedelse (Pensionering) af Gæld, Netto | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -70.041 | -130.732 | -215.32 | -290.581 | -65.22 |
Cash From Operating Activities | -50.24 | -104.461 | -145.895 | -211.389 | -72.109 |
Cash From Operating Activities | 2.108 | 4.312 | 6.499 | 8.593 | 2.079 |
Non-Cash Items | 21.496 | 44.401 | 67.277 | 93.995 | 26.989 |
Changes in Working Capital | -3.803 | -22.442 | -4.351 | -23.396 | -35.957 |
Cash From Investing Activities | -25.405 | 72.132 | 19.124 | -21.626 | -117.878 |
Capital Expenditures | -2.8 | -3.572 | -5.447 | -8.5 | -4.041 |
Other Investing Cash Flow Items, Total | -22.605 | 75.704 | 24.571 | -13.126 | -113.837 |
Cash From Financing Activities | 3.822 | 10.865 | 14.18 | 19.348 | 1.463 |
Issuance (Retirement) of Stock, Net | 3.822 | 10.865 | 14.18 | 19.348 | 1.463 |
Net Change in Cash | -71.823 | -21.464 | -112.591 | -213.667 | -188.524 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Baillie Gifford & Co. | Investment Advisor | 11.1325 | 15119474 | 404423 | 2022-12-31 | LOW |
Biogen Inc | Corporation | 9.8004 | 13310243 | 0 | 2022-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.1736 | 8384653 | 101661 | 2022-09-30 | LOW |
Crestline Investors, Inc. | Hedge Fund | 5.2725 | 7160732 | -300000 | 2022-09-30 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.1599 | 7007844 | -275665 | 2022-09-30 | LOW |
Temasek Holdings Pte. Ltd. | Sovereign Wealth Fund | 4.1057 | 5576041 | 206554 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.0867 | 4192228 | 441528 | 2022-09-30 | LOW |
ARCH Venture Partners | Venture Capital | 2.7013 | 3668749 | -1500000 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.5073 | 3405263 | -1204914 | 2022-09-30 | LOW |
Flagship Ventures | Venture Capital | 1.9291 | 2619968 | 0 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.8058 | 2452456 | -417284 | 2022-09-30 | LOW |
Watts (Ryan J) | Individual Investor | 1.6807 | 2282637 | 82240 | 2023-01-03 | LOW |
Tessier-Lavigne (Marc) | Individual Investor | 1.55 | 2105151 | -40000 | 2022-11-23 | LOW |
Gilder Gagnon Howe & Co. LLC | Hedge Fund | 1.3719 | 1863277 | -93543 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3078 | 1776164 | 69583 | 2022-09-30 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 1.1858 | 1610492 | -349178 | 2022-09-30 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.917 | 1245479 | 15816 | 2022-09-30 | LOW |
Yiheng Capital Management, L.P. | Investment Advisor | 0.7471 | 1014684 | 0 | 2022-09-30 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.7386 | 1003185 | -11973 | 2022-09-30 | LOW |
Casdin Capital, LLC | Hedge Fund | 0.7326 | 995000 | -505000 | 2022-09-30 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com GroupHandlende
Månedlkige, aktive klienter
Månedlig investeringsvolumen
Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Denali Therapeutics Company profile
Om Denali Therapeutics
Denali Therapeutics Inc. er en biofarmaceutisk virksomhed. Virksomheden fokuserer på opdagelse og udvikling af behandlinger til patienter med neurodegenerative sygdomme, herunder Alzheimers sygdom, Parkinsons sygdom, amyotrofisk lateralsklerose (ALS) og andre. Virksomhedens kliniske programmer omfatter et program for hæmmer af leucinrig gentaget kinase 2 (LRRK2), et program for aktivator af eukaryotisk initieringsfaktor 2 B (EIF2B), et program for enzymtransportmiddel: iduronat 2-sulfatase (ETV:IDS), et program for hæmmer af receptorinteragerende serin/threoninproteinkinase 1 (RIPK1) og en anden ikke-CNS penetrerende RIPK1-hæmmer. Virksomheden udvikler sine produktkandidater til at krydse blod-hjernebarrieren (BBB) og virke direkte i hjernen. Virksomhedens pipeline omfatter ca. 15 programmer, der er baseret på virksomhedens TV-teknologi, herunder det førende program ETV:IDS (DNL310). Produktpipelinen omfatter DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL788, DNL343 og DNL758,
Industry: | Bio Therapeutic Drugs |
161 Oyster Point Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080-1910
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com